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Clinical  Inquiries
Do routine eye exams reduce
occurrence of blindness 
from type 2 diabetes?
■ EVIDENCE-BASED ANSWER
Screening eye exams for patients with type 2 
diabetes can detect retinopathy early enough so
treatment can prevent vision loss. Patients with-
out diabetic retinopathy who are systematically
screened by mydriatic retinal photography have a
95% probability of remaining free of sight-threat-
ening retinopathy over the next 5 years. If back-
ground or preproliferative retinopathy is found at
screening (Figure), the 95% probability interval
for remaining free of sight-threatening retino-
pathy is reduced to 12 and 4 months, respective-
ly (strength of recommendation [SOR]: B, based
on 1 prospective cohort study). 
A reliably sensitive screening exam requires
mydriatic retinal photography augmented by 
ophthalmoscopy when photographs are inconclusive
(SOR: A, based on a systematic review). For patients
with diabetes not differentiated by type, photocoagu-
lation significantly decreases visual deterioration
and reduces the chances of blindness (SOR: A, based
on randomized controlled trials [RCT]).
■ EVIDENCE SUMMARY
The Liverpool Diabetic Eye Study1 prospectively
evaluated the risk of vision-threatening retino-
pathy in a cohort that included all patients with
diabetes mellitus who were registered with a gen-
eral practitioner and were not under the care of
an ophthalmologist. A subgroup of 4770 patients
with type 2 diabetes who did not have sight-
threatening retinopathy at baseline underwent at
least 1 additional screen. Screening included non-
stereoscopic 3-field (45° or 50° field) mydriatic
photography. Median follow-up was 3.5 years
(range, 1–8.5 years). 
The patients were divided into cohorts based
on level of demonstrated retinopathy. The mean
screening interval for a 95% probability of
remaining free of sight-threatening retinopathy
was calculated for each grade of baseline
retinopathy. Screening patients with no retino-
pathy every 5 years provided a 95% probability of
remaining free of sight-threatening retinopathy.
Patients with background retinopathy must be
screened annually to achieve the same result, and
patients with mild preproliferative retinopathy
need to be screened every 4 months (Table).
A systematic review2 of multiple small English-
language studies evaluating screening and moni-
toring of diabetic retinopathy found consistent
results. Screening by direct or indirect ophthal-
moscopy alone detected 65% of patients with
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tiated by type of diabetes, were each treated in 1
eye chosen at random with a xenon-arc photoco-
agulator. Patients underwent follow-up treat-
ments to the treated eye by clinical indication.
The untreated eyes were observed as controls.
Blindness occurred significantly less often in the
treated eyes (19% total after 5 to 7 years) than in
the control eyes (39%; NNT=5 to prevent 1 blind
eye). Patients without proliferative retinopathy at
onset experienced the most dramatic slowing of
deterioration; photocoagulation was more useful
in maintaining than in improving vision.
■ RECOMMENDATIONS FROM OTHERS
The American Diabetes Association 2003 Clinical
Practice Recommendations5 state that patients
with type 2 diabetes should have an initial dilated
and comprehensive eye examination by an oph-
thalmologist or optometrist shortly after diagno-
sis of diabetes. An ophthalmologist or optometrist
who is knowledgeable and experienced in diag-
nosing diabetic retinopathy and is aware of its
management should repeat subsequent examina-
tions for both type 1 and type 2 diabetic patients
sight-threatening retinopathy. Screening by mydri-
atic retinal photography, augmented by ophthal-
moscopy when the photographs were inconclusive,
detected 88% to 100% of such cases.
An RCT of 1700 patients with diabetes and
retinopathy evaluated preservation of vision with
photocoagulation.3 Patients were not differentiat-
ed by type of diabetes. Each patient had initial
and follow-up stereoscopic fundus photography.
One eye was selected at random to receive treat-
ment and the other remained untreated to serve
as a control. Because of the magnitude of differ-
ence in vision between the eyes, the study was
halted at 2 years to permit photocoagulation of
the untreated eyes. Patients whose eyes had new
vessels on or near the disk lost vision (defined as
visual acuity less than 5/200) more often in
untreated eyes (18.3% cumulative rate at 2
years) compared with treated eyes (6.4%; num-
ber needed to treat [NNT]=8.4).
Another RCT4 of patients with diabetes
showed that photocoagulation maintained vision
in diabetic retinopathy if the disease was not too
advanced. Ninety-nine patients, also not differen-
F I G U R E   
Background (nonproliferative) diabetic retinopathy
is characterized by macular retinal exudates, edematous
retinal thickening, dot and blot retinal hemorrhages,
and retinal capillary microaneurysms. 
Proliferative diabetic retinopathy. Note the network 
of abnormal preretinal new blood vessels just super-
otemporal to the macula and the linear accumulations
of blood in the preretinal vitreous below the macula.
Nonproliferative and proliferative diabetic retinopathy
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What is the most effective
diagnostic evaluation 
of streptococcal pharyngitis? 
■ EVIDENCE-BASED ANSWER
Standardized clinical decision rules, such as the
Centor criteria, can identify patients with low
likelihood of group A beta-hemolytic streptococ-
cal (GABHS) pharyngitis who require no further
evaluation or antibiotics (strength of recommen-
dation [SOR]: A, based on validated cohort stud-
ies). For patients at intermediate and higher risk
by clinical prediction rules, a positive rapid anti-
gen detection (RAD) test is highly specific for
GABHS (SOR: A, based on systematic reviews of
diagnostic trials). 
A negative RAD test result, using the best
technique, approaches the sensitivity of throat
culture (SOR: B, based on retrospective cohort
studies). In children and populations with an
increased prevalence of GABHS and GABHS com-
plications, adding a backup throat culture reduces
the risk of missing GABHS due to false-negative
RAD results (SOR: C, based on expert opinion).
■ EVIDENCE SUMMARY
In the US, GABHS is the cause of acute pharyn-
gitis in 5% to 10% of adults and 15% to 30% of
children. It is the only commonly occurring cause
of pharyngitis with an indication for antibiotic
annually. Examinations are required more fre-
quently if retinopathy is progressing.
Charles G. Tubbs, MD, Abraham Safeek, MD,
Helen G. Mayo, MLS, University of Texas Southwestern
Medical Center, Dallas
■ CLINICAL COMMENTARY
Screen for retinal complications early, 
regularly, by an experienced eye doctor
Family physicians play a central role in the dia-
betes care team. They must not only achieve
good blood sugar control, but also monitor for
complications and coordinate their treatment.
Educating patients and reaching common
ground with them is essential for success.
Evidence suggests that screening for eye compli-
cations reduces blindness. Patients with early
retinopathy changes are usually asymptomatic;
therefore it takes a committed and educated
patient to comply with screening recommenda-
tions. Also, many patients have the misconcep-
tion that a visual acuity exam by an optometrist
is sufficient for their diabetes eye screening.
Family physicians must convey the importance
of screening for retinal complications early, reg-
ularly and by an optometrist or ophthalmologist
experienced in management of diabetes.
Tsveti Markova, MD, Department of Family Medicine,
Wayne State University, Detroit, Mich
Screening frequency 
for sight-threatening retinopathy
Stage of Screening 
retinal disease frequency*
None 5 years
Background retinopathy 1 year
Mild preproliferative 4 months
retinopathy
*For 95% chance of remaining free of sight-threatening
retinopathy.
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